KYMR
Kymera Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.75 EPS, $28.8M rev
Last earnings -0.5% on 2026-04-30
$114.50
▲ +14.65%$114.50▲ +146.55%
over 1Y
L $37.68EODHDH $114.50
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+14.6%
1W+11.1%
1M+23.6%
3M+26.5%
YTD+37.3%
1Y+115.1%
Hold
Conviction
Horizon
Long (>12mo)
Street · 30 analysts
Strong Buy
Pre-revenue TPD biotech with a promising oral-degrader pipeline and marquee partners, but deep losses make it a binary, speculative bet.
Kymera is a clinical-stage leader in targeted protein degradation (TPD), aiming to deliver oral small molecules with biologics-like activity in immunology. The scientific and strategic validation is real: lead STAT6 degrader KT-621 has entered the BROADEN2 (atopic dermatitis) and BREADTH (asthma) Phase 2b trials, an oral IRF5 degrader (KT-579) is in Phase 1, and the company has high-profile collaborations with Sanofi (IRAK4 degrader KT-485, advancing to clinical testing in 2026) and Gilead (CDK2 molecular glues announced June 2025). The addressable immunology market is large, and oral convenience versus injectable biologics is a credible differentiator.
Sources: SEC EDGAR (CIK 0001815442, latest 10-Q filed 2026-04-30) · EODHD · analysis by claude-code · as of 6/21/2026, 8:53:25 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.